Sun Pharma Q2 Results Review - Dolat Capital Sees Limited Upside, Maintains 'Reduce' Rating

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.